ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
•17 Dec 2025 09:48

Zhejiang Sanhua Intelligent Controls IPO Lockup - US$800m Cornerstone Release

Zhejiang Sanhua Intelligent Controls (2050 HK), raised around US$1.4bn in its H-share listing. The lockup on its cornerstone investors is set to...

Logo
615 Views
Share
•16 Dec 2025 14:03

OmniVision Integrated Circuits Group A/H Listing - PHIP Updates and Thoughts on A/H Premium

Omnivision Intgrated Circuit (603501 CH, OVIC), a semiconductor company, aims to raise around US$1bn in its H-share listing. In this note, we talk...

Logo
548 Views
Share
•14 Dec 2025 10:15

A-H Premium Weekly (Dec 12th): MCC, China Merchants Securities, Chongqing Rural Commercial Bank

We analyzed A-H premium changes in the past week and highlight A-H premium changes for MCC, China Merchants Securities, Chongqing Rural Commercial...

Logo
464 Views
Share
•08 Dec 2025 08:09

Suzhou Novosense A/H Trading - Weakest Demand but Highest Concentration

Suzhou Novosense Microelectron (688052 CH), an analog chips producer, raised around US$285m in its H-share listing. In this note, we talk about the...

Logo
417 Views
Share
•07 Dec 2025 10:15

A-H Premium Weekly (Dec 5th): Jiangsu Expressway, China Vanke, Fibocom Wireless, Fuyao Glass

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Jiangsu Expressway, China Vanke, Fibocom Wireless, Fuyao Glass.

Logo
496 Views
Share
x